Value of Thymosin α1 Combined With Blood Purification to Increase Successful Rescues of Shock Patients

What Was Tested

Researchers studied Thymosin Alpha-1 in this randomized controlled trial publication.

The study intended to explore the effects of Thymosin α1 (T-α1) plus blood purification (BP) on SS patients under the emergency green channel (GC), a fast and efficient service system that hospitals provide for acutely and critically ill patients.

Who Took Part

The study group was 86 patients.

The study took place in the Emergency Department at the Second Affiliated Hospital of Xi'an Jiaotong University in Xi'an, Shaanxi, China.

Participants were 86 SS patients who came to the hospital for treatment between June 2019 and January 2021.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Thymosin Alpha-1 group and the comparison group should start out alike.

The research team designed a randomized controlled study.

The research team numbered the patients in sequence according to the admission time of the patients, and then randomly numbered them by the computer, and assigned participants to an intervention or a control group, with 43 participants in the intervention group receiving T-α1 plus BP therapy and 43 participants in the control group receiving BP treatment only.

What Was Measured

PubMed files the paper under topics including Cytokines, Inflammation Mediators, Intensive Care Units, Thymalfasin and Thymosin.

What This Means in Plain Language

The paper is a randomized study of Thymosin Alpha-1 in 86 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Alternative therapies in health and medicine), a journal based in United States.

More context: the Thymosin Alpha-1 compound page, all human trials.